Conventional and alternative antifungal therapies to oral candidiasis
AUTOR(ES)
Anibal, Paula Cristina, Sardi, Janaina de Cássia Orlandi, Peixoto, Iza Teixeira Alves, Moraes, Julianna Joanna de Carvalho, Höfling, José Francisco
FONTE
Brazilian Journal of Microbiology
DATA DE PUBLICAÇÃO
2010-12
RESUMO
Candida-associated denture stomatitis is the most common form of oral candidal infection, with Candida albicans being the principal etiological agent. Candida adheres directly or via an intermediary layer of plaque-forming bacteria to denture acrylic. Despite antifungal therapy to treat denture stomatitis, infection is reestablished soon after the treatment ceases. In addition, many predisposing factors have been identified as important in the development of oral candidiasis, including malnourishment, common endocrine disorders, such as diabetis mellitus, antibacterial drug therapy, corticosteroids, radiotherapy and other immunocompromised conditions, such as acquired immunodeficiency syndrome (AIDS). These often results in increased tolerance to the most commonly used antifungals. So this review suggests new therapies to oral candidiasis.
Documentos Relacionados
- Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats
- Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis
- Alternative Therapies for PKU
- Antifungal Efficacy of GM237354, a Sordarin Derivative, in Experimental Oral Candidiasis in Immunosuppressed Rats
- Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.